menu search

REGN / Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 2, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Read More
Posted: Sep 28 2023, 16:05
Author Name: GlobeNewsWire
Views: 112561

REGN News  

Regeneron Pharma's adjusted earnings beat estimates

By Market Watch
November 2, 2023

Regeneron Pharma's adjusted earnings beat estimates

Regeneron Pharmaceuticals Inc.'s stock REGN, +1.46% rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjus more_horizontal

Regeneron beats quarterly profit estimates on eczema treatment strength

By Reuters
November 2, 2023

Regeneron beats quarterly profit estimates on eczema treatment strength

Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent. more_horizontal

Curious about Regeneron (REGN) Q3 Performance? Explore Wall Street Estimates for Key Metrics

By Zacks Investment Research
November 1, 2023

Curious about Regeneron (REGN) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understandi more_horizontal

2 Healthcare Stocks Near 52-Week Highs Still Worth Buying

By The Motley Fool
October 16, 2023

2 Healthcare Stocks Near 52-Week Highs Still Worth Buying

Healthcare stocks, on balance, haven't been great investments in 2023. Regeneron Pharmaceuticals and Vertex Pharmaceuticals have been two glaring exce more_horizontal

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

By Zacks Investment Research
October 6, 2023

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely bea more_horizontal

This Market-Beating Stock Just Gave Investors More Reasons to Invest

By The Motley Fool
October 5, 2023

This Market-Beating Stock Just Gave Investors More Reasons to Invest

Regeneron recently earned a key regulatory approval. The company also expanded its pipeline with an acquisition. more_horizontal

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

By GlobeNewsWire
September 28, 2023

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quart more_horizontal

This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost

By The Motley Fool
September 20, 2023

This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost

Regeneron's sales growth rate has been struggling over the past year. Revenue from its top-selling drug, Eylea, fell 7% in the most recent quarter. more_horizontal


Search within

Pages Search Results: